<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Type 1 diabetes mellitus: Prevention and disease-modifying therapy</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Type 1 diabetes mellitus: Prevention and disease-modifying therapy</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Type 1 diabetes mellitus: Prevention and disease-modifying therapy</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Carla J Greenbaum, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sandra Lord, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Cate Speake, PhD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Irl B Hirsch, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Joseph I Wolfsdorf, MD, BCh</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Katya Rubinow, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 02, 2024.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>One hundred years after its first clinical use, insulin remains the primary treatment for type 1 diabetes mellitus, but it does not modify the underlying autoimmune process. Furthermore, despite the advent of more physiologic insulin analogs, continuous glucose monitoring, and automated insulin delivery methods, most individuals living with type 1 diabetes do not meet the therapeutic targets that are associated with a lower risk of long-term complications [<a href="#rid1">1,2</a>]. Type 1 diabetes management is expensive, complicated, and exacts a mental and emotional toll on individuals with diabetes and their loved ones [<a href="#rid3">3-6</a>]. Therefore, alternative approaches that modify the natural history of type 1 diabetes, rather than solely treat hyperglycemia, could dramatically improve both quality of life and health outcomes for individuals with type 1 diabetes.</p><p>This topic will review strategies to prevent or delay clinical type 1 diabetes during preclinical stages of disease, as well as strategies to preserve insulin secretion after the onset of clinical disease. The pathophysiology and etiology of type 1 diabetes are discussed elsewhere, as are strategies for identifying and screening individuals at elevated disease risk. (See  <a class="medical medical_review" href="/d/html/1800.html" rel="external">"Pathogenesis of type 1 diabetes mellitus"</a> and  <a class="medical medical_review" href="/d/html/1791.html" rel="external">"Type 1 diabetes mellitus: Disease prediction and screening"</a>.)</p><p class="headingAnchor" id="H167832922"><span class="h1">STAGES OF TYPE 1 DIABETES</span><span class="headingEndMark"> — </span>Type 1 diabetes has a long preclinical period during which endogenous insulin secretion remains relatively stable, followed by a peridiagnostic period when secretion declines more rapidly [<a href="#rid7">7-10</a>]. (See  <a class="medical medical_review" href="/d/html/1791.html" rel="external">"Type 1 diabetes mellitus: Disease prediction and screening", section on 'Stages of type 1 diabetes'</a>.)</p><p>This long preclinical period comprises well-defined stages of disease progression, affording an opportunity to intervene with disease-modifying therapies. Virtually all individuals with preclinical disease progress to clinical type 1 diabetes  (<a class="graphic graphic_table graphicRef141622" href="/d/graphic/141622.html" rel="external">table 1</a>).</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Stage 1</strong> – Stage 1 diabetes is an asymptomatic period defined by seroconversion with the presence of at least two diabetes-related autoantibodies but preserved normoglycemia. This is considered the onset of type 1 diabetes.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Stage 2</strong> – Stage 2 diabetes is characterized by asymptomatic progression to dysglycemia.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Stage 3</strong> – Stage 3 diabetes is the onset of clinical disease and defined by glycemic criteria. Individuals with stage 3 diabetes usually but not uniformly have hyperglycemia-related symptoms.</p><p></p><p>In individuals with preclinical (stage 1 or stage 2) type 1 diabetes, the goal of disease-modifying therapies is to prevent or delay the onset of clinical disease. In individuals with clinical (stage 3) type 1 diabetes, the goal of disease-modifying therapy is to preserve beta cell function and insulin secretion.</p><p class="headingAnchor" id="H2459282982"><span class="h1">PREVENTING OR DELAYING CLINICAL DISEASE IN HIGH-RISK INDIVIDUALS</span></p><p class="headingAnchor" id="H3460514862"><span class="h2">Teplizumab</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="140208" href="/d/drug information/140208.html" rel="external">Teplizumab</a>, a humanized anti-CD3 monoclonal antibody, is the only therapy with regulatory approval in the United States for delaying the onset of clinical type 1 diabetes in individuals with preclinical disease.</p><p class="headingAnchor" id="H3858286211"><span class="h3">Clinical use</span><span class="headingEndMark"> — </span>In the United States, <a class="drug drug_general" data-topicid="140208" href="/d/drug information/140208.html" rel="external">teplizumab</a> is approved for individuals aged 8 years and older who have stage 2 type 1 diabetes (≥2 diabetes-related autoantibodies and dysglycemia)  (<a class="graphic graphic_table graphicRef141622" href="/d/graphic/141622.html" rel="external">table 1</a>) and is administered as a single 14-day course of daily intravenous infusions.</p><p>The implementation of <a class="drug drug_general" data-topicid="140208" href="/d/drug information/140208.html" rel="external">teplizumab</a> in clinical practice is evolving and varies regionally. For individuals who meet criteria for teplizumab therapy, the choice to initiate treatment should be individualized based on patient and family preferences and the availability of infrastructure to support treatment infusions.</p><p>The availability of <a class="drug drug_general" data-topicid="140208" href="/d/drug information/140208.html" rel="external">teplizumab</a> represents a paradigm shift in the treatment of type 1 diabetes; with enhanced understanding of disease pathogenesis and progression, type 1 diabetes can be identified and treated in its preclinical stages before the development of symptomatic hyperglycemia. Improved clinical systems to identify and monitor individuals with preclinical disease will be critical as other disease-modifying therapies become available and the use of these therapies expands in clinical practice. (See  <a class="medical medical_review" href="/d/html/1791.html" rel="external">"Type 1 diabetes mellitus: Disease prediction and screening", section on 'Screening for diabetes-related autoantibodies'</a>.)</p><p class="headingAnchor" id="H3057189649"><span class="h3">Efficacy and side effects</span><span class="headingEndMark"> — </span>Regulatory approval of <a class="drug drug_general" data-topicid="140208" href="/d/drug information/140208.html" rel="external">teplizumab</a> in the United States was based on a landmark prevention trial in which 76 individuals (median age 14 years) with stage 2 diabetes (≥2 diabetes-related autoantibodies, impaired glucose tolerance) and a relative with type 1 diabetes were randomly assigned to a single 14-day course of once-daily infusions of either teplizumab (n = 44) or placebo (n = 32) [<a href="#rid11">11</a>]. Over a median follow-up of approximately two years, teplizumab delayed the onset of clinical type 1 diabetes by a median of 24 months  (<a class="graphic graphic_figure graphicRef81644" href="/d/graphic/81644.html" rel="external">figure 1</a>), and 25 of 44 teplizumab recipients remained disease-free compared with 9 of 32 placebo recipients (57 versus 28 percent, respectively). In a follow-up analysis with a median 923 days of observation, teplizumab conferred a median delay in type 1 diabetes diagnosis of 32.5 months, and 50 percent of teplizumab recipients remained disease-free compared with 22 percent of placebo recipients  (<a class="graphic graphic_figure graphicRef141628" href="/d/graphic/141628.html" rel="external">figure 2</a>) [<a href="#rid12">12</a>]. The efficacy results of this small trial may differ from effectiveness in clinical practice.</p><p>Among clinical trial participants, the primary side effects of <a class="drug drug_general" data-topicid="140208" href="/d/drug information/140208.html" rel="external">teplizumab</a> treatment were transient lymphopenia, rash, headache, transient liver transaminase elevation, and nausea [<a href="#rid11">11</a>]. Lymphocyte count declined early during teplizumab treatment but self-resolved in all participants  (<a class="graphic graphic_figure graphicRef141624" href="/d/graphic/141624.html" rel="external">figure 3</a>). The teplizumab prevention trial was relatively small and of short duration, which limits conclusions about adverse events that are less common.</p><p class="headingAnchor" id="H3898839006"><span class="h2">Therapies in development for preclinical disease</span><span class="headingEndMark"> — </span>Studies are underway to test the efficacy of several immune-modulating treatments in individuals with both stage 1 (≥2 diabetes-related autoantibodies with normoglycemia) and stage 2 (≥2 diabetes-related autoantibodies and dysglycemia) type 1 diabetes  (<a class="graphic graphic_table graphicRef141622" href="/d/graphic/141622.html" rel="external">table 1</a>). None of these therapies is available for clinical use.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Antithymocyte globulin</strong> – Antithymocyte globulin (ATG) comprises animal-derived antibodies that deplete B cells and T cells. This treatment was shown to preserve insulin secretion in clinically overt (stage 3) type 1 diabetes, prompting design of a subsequent efficacy trial in individuals with preclinical disease [<a href="#rid13">13</a>]. (See <a class="local">'Lymphocyte-directed therapies'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Abatacept</strong> – <a class="drug drug_general" data-topicid="8526" href="/d/drug information/8526.html" rel="external">Abatacept</a> is a cytotoxic T lymphocyte antigen 4 (CTLA4) immunoglobulin that blocks T cell costimulation. Abatacept can preserve beta cell function in clinically overt (stage 3) type 1 diabetes, and this finding led to a follow-up trial in individuals with preclinical (stage 1) disease. In the follow-up trial, abatacept improved beta cell function at 12 months compared with placebo; however, 12 months after treatment ended, beta cell function was the same in both groups. Abatacept also did not delay progression to stage 2 or stage 3 disease [<a href="#rid14">14</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hydroxychloroquine</strong> – <a class="drug drug_general" data-topicid="8541" href="/d/drug information/8541.html" rel="external">Hydroxychloroquine</a> is a well-tolerated medication that is approved for the treatment of autoimmune conditions including rheumatoid arthritis and systemic lupus erythematosus. It is under investigation as a therapy to delay the progression of preclinical (stage 1) type 1 diabetes [<a href="#rid15">15,16</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Oral insulin</strong> – Oral insulin has been tested in multiple trials to delay or prevent progression to clinical (stage 3) disease in individuals with preclinical disease or high genetic risk for type 1 diabetes. None of the trials have demonstrated efficacy for the prevention or delay of type 1 diabetes, but post hoc analyses indicate that oral insulin may benefit selected individuals with high insulin autoantibody titers or those closer to clinical diagnosis. In the Diabetes Prevention Trial (DPT-1), 372 autoantibody-positive family members of people with type 1 diabetes were randomly assigned to daily oral insulin or placebo [<a href="#rid17">17</a>]. In the overall cohort, oral insulin did not prevent disease progression. In a post hoc analysis, oral insulin delayed the onset of clinical disease by 4.5 and 10 years in participants with insulin autoantibody titers ≥80 and ≥300 nU/mL, respectively [<a href="#rid18">18,19</a>]. In a subsequent trial, oral insulin similarly did not delay progression to clinical disease, but in an independently randomized cohort of 55 participants with low first-phase insulin secretion at baseline, oral insulin conferred a 31-month delay in disease progression [<a href="#rid20">20</a>].</p><p></p><p class="bulletIndent1">Oral insulin also is being tested for primary prevention of islet autoimmunity and clinical type 1 diabetes in genetically at-risk children. In a trial in 25 genetically at-risk children who had not yet developed autoantibodies, oral insulin (67.5 mg daily) was safe and induced a regulatory immune response [<a href="#rid21">21</a>]. These preliminary data prompted a subsequent, ongoing trial [<a href="#rid22">22</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Intranasal insulin</strong> – Trials testing intranasal insulin have demonstrated that therapy is safe and elicits an immune response but is ineffective for delaying type 1 diabetes progression [<a href="#rid23">23-25</a>]. Additional studies are testing whether a higher dose or alternative dosing schedule may delay disease progression.</p><p></p><p class="headingAnchor" id="H1158350887"><span class="h2">Therapies without benefit for preclinical disease</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Nicotinamide</strong> – <a class="drug drug_general" data-topicid="9696" href="/d/drug information/9696.html" rel="external">Nicotinamide</a> prevents autoimmune diabetes in nonobese diabetic (NOD) mice. However, in a trial in 552 individuals with preclinical type 1 diabetes (autoantibody positivity, relative with type 1 diabetes), daily treatment with extended-release nicotinamide (1.2 g/m<sup>2</sup>) over a course of five years had no effect on type 1 diabetes progression [<a href="#rid26">26</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Parenteral insulin</strong> – Early treatment with exogenous insulin was hypothesized to "rest" dysfunctional beta cells and reduce their immune-mediated destruction. An arm of the DPT-1 trial tested low-dose ultralente insulin in 339 participants with preclinical disease and high risk for progression. Therapy was safe and did not cause excessive hypoglycemia but did not delay progression to clinical disease [<a href="#rid23">23</a>].</p><p></p><p class="headingAnchor" id="H4116836099"><span class="h1">PRESERVING INSULIN SECRETION IN CLINICAL DISEASE</span><span class="headingEndMark"> — </span>At the time of diagnosis, most patients with type 1 diabetes still have clinically meaningful endogenous insulin production, which is measured as C-peptide. C-peptide is cosecreted with insulin in equimolar amounts and reflects endogenous insulin secretion in individuals treated with insulin therapy. The aim of immunotherapy in early clinical disease is to preserve remaining insulin secretion, which is associated with reduced glycemic variability, lower risk of long-term complications, and lower risk of hypoglycemia.</p><p class="headingAnchor" id="H2793238307"><span class="h2">Clinical benefits of preserved insulin secretion</span><span class="headingEndMark"> — </span>Historically, type 1 diabetes was thought to uniformly cause absolute deficiency of endogenous insulin, typically within a few years of diagnosis. However, endogenous insulin secretion persists in some individuals for years or even decades after diagnosis. For example, a T1D Exchange substudy of 919 individuals (aged 5 to 88 years) with variable disease duration (3 to 81 years, median duration 13 years) found that the overall frequency of detectable, nonfasting C-peptide (≥0.017 nmol/L [0.05 ng/mL]) was 29 percent [<a href="#rid27">27</a>]. In a separate cross-sectional analysis in 924 individuals with a median diabetes duration of 19 years, 80 percent of individuals had detectable post-meal urine C-peptide [<a href="#rid28">28</a>]. In cohorts of individuals with a mean duration of type 1 diabetes &gt;50 years, the frequency of detectable C-peptide concentrations has ranged from 32 to 67 percent [<a href="#rid29">29,30</a>]. The variable frequency of detectable C-peptide concentrations across studies may in part reflect the substantial increase in assay sensitivity over time.</p><p>In individuals with type 1 diabetes, data from natural history studies, intervention studies, and transplant studies show that preserved beta cell function reduces the risk of long-term microvascular complications and severe hypoglycemia. However, the magnitude and duration of preserved insulin secretion needed to confer these benefits have not been clearly established. Preserved beta cell function may reduce risk of diabetes-related complications in part through improved glycemia; the extent to which preserved beta cell function and intensive glucose management provide independent and additive protection from risk of diabetes-related complications has not been clearly established.</p><p class="headingAnchor" id="H1596826014"><span class="h3">Lower risk of diabetes-related complications</span><span class="headingEndMark"> — </span>Preserved insulin secretion strongly associates with a reduced risk of diabetes-related microvascular complications. The protective effects of preserved insulin secretion were shown in a subgroup analysis from the Diabetes Control and Complications Trial (DCCT) that included 303 individuals with type 1 diabetes (duration one to five years) and preserved C-peptide production (stimulated C-peptide level &gt;0.20 nmol/L [0.6 ng/mL]). In this subgroup, participants who were randomly assigned to intensive insulin therapy (three or more daily insulin injections or continuous subcutaneous insulin infusion) exhibited both a higher rate of preserved C-peptide response and a lower risk of retinopathy progression or microalbuminuria than those who received conventional therapy (one or two daily insulin injections) [<a href="#rid31">31</a>]. Moreover, within the group assigned to intensive insulin therapy, individuals who retained a C-peptide response had a 50 percent lower risk of retinopathy progression than those who lost C-peptide response during the study.</p><p>In cohorts of people living with type 1 diabetes for 50 years or longer, continued production of endogenous insulin is associated with relative protection from long-term diabetes-related complications including retinopathy, kidney disease, and vascular disease. Cross-sectional analyses have shown that among individuals with longstanding type 1 diabetes (mean duration &gt;50 years), protection from diabetes-related complications is associated with lower daily insulin doses (approximately 0.5 units/kg body weight) [<a href="#rid32">32,33</a>], consistent with some degree of preserved insulin secretion. Notably, one of these studies also demonstrated that this relative protection from complications was not associated with current glycated hemoglobin (A1C) or longitudinal (over 15 years) A1C trends [<a href="#rid33">33</a>], suggesting that preserved insulin secretion may impart protection independent of glycemia.</p><p class="headingAnchor" id="H3120085549"><span class="h3">Improved glycemia</span><span class="headingEndMark"> — </span>In individuals with type 1 diabetes, clinical data suggest that preserved insulin secretion promotes overall glycemic management, reduced glycemic variability, and avoidance of hypoglycemia. In the DCCT, participants who were randomly assigned to intensive insulin therapy had a reduced risk of diabetes-related complications but a two- to three-fold greater risk of severe hypoglycemia compared with those who received conventional therapy [<a href="#rid34">34</a>]. However, in a subgroup analysis of 303 participants with preserved C-peptide production at baseline (stimulated C-peptide level &gt;0.20 nmol/L [0.6 ng/mL]), those who retained a C-peptide response during intensive insulin therapy had both a lower A1C and a 65 percent lower risk of severe hypoglycemia than intensively treated participants who lost a C-peptide response [<a href="#rid31">31</a>].</p><p>Similarly, in an analysis from the Inducing Remission in New-Onset T1D with Alefacept (T1DAL) trial in individuals with newly diagnosed type 1 diabetes (aged 12 to 35 years), stimulated C-peptide level was inversely correlated with A1C, glycemic variability, and hypoglycemia after two years of follow-up [<a href="#rid35">35</a>]. These correlations were evident irrespective of treatment group assignment, further suggesting that preserved C-peptide, rather than the treatment intervention, was responsible for the observation [<a href="#rid35">35</a>].</p><p>Observational data from islet cell transplant studies provide indirect corroboration of the protective effects of preserved beta cell function on glycemia. In a study of 12 islet cell transplant recipients, stimulated C-peptide level was inversely correlated with mean interstitial glucose, glycemic variability, time spent outside the glucose target range, and hypoglycemia risk [<a href="#rid36">36</a>].</p><p class="headingAnchor" id="H2521030802"><span class="h3">Degree of preserved insulin secretion needed for clinical benefit</span><span class="headingEndMark"> — </span>Collective clinical data suggest that even minimal residual insulin secretion provides clinical benefit in individuals with type 1 diabetes, although specific benefits may require different thresholds of insulin secretion. For example, in a retrospective analysis of DCCT data that stratified participants in the intensive insulin therapy arm by stimulated C-peptide level, those with a stimulated C-peptide &gt;0.04 nmol/L (0.12 ng/mL) at study entry exhibited reduced risk of retinopathy and diabetic kidney disease [<a href="#rid37">37</a>]. However, only those participants with a stimulated C-peptide level &gt;0.2 nmol/L (0.6 ng/mL) experienced lower frequency of severe hypoglycemia [<a href="#rid37">37</a>]. An investigation of 677 islet cell transplant recipients followed for a mean of 4.6 years found that stimulated C-peptide &gt;0.97 nmol/L (2.9 ng/mL) provided optimal protection from severe hypoglycemia [<a href="#rid38">38</a>]. In another analysis of DCCT data, any incremental increase in C-peptide above the point of detection (0.03 nmol/L [0.09 ng/mL]) was associated with lower A1C, lower daily insulin usage, fewer episodes of hypoglycemia, and lower risk of retinopathy [<a href="#rid39">39</a>].</p><p>Further supporting the protective effects of preserved insulin secretion, an analysis from a natural history cohort of 6076 people with type 1 diabetes found that nonfasting C-peptide level was inversely correlated with both incident retinopathy and frequency of severe hypoglycemia [<a href="#rid40">40</a>]. Notably, in this cohort, a continuous reduction in severe hypoglycemia risk was associated with C-peptide levels to the lower limit of detection (0.003 nmol/L [0.009 ng/mL]), markedly lower than the protective threshold observed in the DCCT intensive treatment cohort. The reduction in retinopathy risk also was associated with the lower A1C levels evident in individuals with preserved C-peptide.</p><p>Data from islet cell transplant studies also offer indirect evidence of the protective effects of even minimal endogenous insulin production. In a study of 23 individuals with type 1 diabetes who underwent islet cell transplant, minimal beta cell function after transplant was sufficient to abrogate severe hypoglycemia and impaired awareness of hypoglycemia, even when insulin production from the transplanted islets was inadequate to improve mean glucose, reduce glycemic variability, or enable insulin independence [<a href="#rid41">41</a>].</p><p class="headingAnchor" id="H3335703530"><span class="h2">Promising investigational therapies to preserve insulin secretion</span><span class="headingEndMark"> — </span>As in all other immune-mediated diseases, immunotherapy does not cure type 1 diabetes, but multiple therapies have demonstrated the potential to alter the natural history of disease. Since the 1980s, dozens of short-term therapies have been tested in new-onset (stage 3) type 1 diabetes. Although none is approved for clinical use in type 1 diabetes, several have demonstrated an acceptable risk profile and the capacity to modify the underlying disease and preserve insulin secretion.</p><p>Regardless of the therapy's mechanism of action, the results in trials with positive outcomes are similar: the rate of C-peptide decline differs between drug- and placebo-treated individuals soon after randomization, and C-peptide later declines in parallel in both groups [<a href="#rid42">42</a>]. These findings suggest that immunotherapy can modify the natural history of type 1 diabetes, as the early treatment benefit leads to a sustained increase in C-peptide in drug-treated groups compared with control groups. Further, this benefit endures for years after treatment. For example, two days of therapy with antithymocyte globulin resulted in greater insulin secretion than placebo two years after treatment  (<a class="graphic graphic_figure graphicRef141629" href="/d/graphic/141629.html" rel="external">figure 4</a>) [<a href="#rid42">42</a>]. (See <a class="local">'Lymphocyte-directed therapies'</a> below.)</p><p>Findings from several stage 3 trials suggest that treatment response is most evident during the time of more rapid loss of insulin secretion; such rapid loss is often seen in younger children or in those closer to clinical diagnosis.</p><p class="headingAnchor" id="H2836170939"><span class="h3">Cytokine-directed therapies</span><span class="headingEndMark"> — </span>A hallmark of type 1 diabetes pathophysiology is beta cell infiltration by CD4+ and CD8+ T cells. These lymphocytes can release cytokines that may variably facilitate beta cell destruction, beta cell repair, or tolerance of self-antigens; thus, targeting these cytokines or their downstream pathways represents a potential therapeutic strategy for preserving endogenous insulin secretion in type 1 diabetes. The pathophysiology of type 1 diabetes is reviewed in detail separately. (See  <a class="medical medical_review" href="/d/html/1800.html" rel="external">"Pathogenesis of type 1 diabetes mellitus"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Anti-tumor necrosis factor (TNF) therapies</strong> – The anti-TNF agents <a class="drug drug_general" data-topicid="8925" href="/d/drug information/8925.html" rel="external">etanercept</a> and <a class="drug drug_general" data-topicid="9086" href="/d/drug information/9086.html" rel="external">golimumab</a> have been shown to transiently preserve insulin secretion in new-onset type 1 diabetes. Etanercept<strong> </strong>was tested in a pilot study in 18 individuals (aged 3 to 18 years) with type 1 diabetes diagnosed within 100 days who were randomly assigned to 24 weeks of etanercept or placebo injections [<a href="#rid43">43</a>]. At the end of treatment, stimulated C-peptide area-under-the-curve (AUC) increased 39 percent from baseline in the etanercept group but decreased by 20 percent in the placebo group. In a trial in 84 individuals (aged 6 to 21 years) recently diagnosed with type 1 diabetes, participants were randomly assigned to the anti-TNF agent golimumab or placebo [<a href="#rid44">44</a>]. After 52 weeks of treatment, golimumab treatment led to a higher stimulated C-peptide AUC than placebo (0.64 versus 0.43 pmol/mL, respectively), and this benefit was sustained for 52 weeks following treatment [<a href="#rid45">45</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Interleukin (IL)-2 therapy</strong> – The IL-2 pathway<strong> </strong>regulates the expansion of regulatory T cells, and some clinical studies have implicated deficient IL-2 production or regulatory T cells in type 1 diabetes [<a href="#rid46">46,47</a>]. However, a trial of combination therapy with rapamycin and IL-2 was ended early when a transient worsening of beta cell function was observed, despite the anticipated treatment-induced increase in regulatory T cells [<a href="#rid48">48</a>]. This trial and others revealed IL-2's narrow therapeutic dosing window. Different dosing strategies and modified versions of IL-2 are being developed to stimulate the desired expansion of regulatory T cells while avoiding off-target effects.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Anti-IL-12, anti-IL-23, and anti-IL-17 therapies</strong> – IL-12 and IL-23 contribute to the production of interferon (IFN) lambda and IL-17, key cytokines in the generation of pathogenic effector T cells in type 1 diabetes. Antibodies to IL-12, IL-23, and IL-17 are being tested in adults with new-onset type 1 diabetes.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Janus kinase (JAK)/signal transducer and activator of transcription (STAT) pathway inhibition</strong> – The JAK/STAT signaling pathway plays myriad roles in immune function including the regulation of cytokine receptors. This pathway has been implicated in immune-mediated beta cell destruction in type 1 diabetes, and blockade of this pathway prevents and reverses diabetes in the nonobese diabetic (NOD) mouse model [<a href="#rid49">49</a>]. In a trial in 91 individuals (aged 10 to 30 years) with new-onset type 1 diabetes (diagnosed within 100 days), participants were randomly assigned to daily treatment with the oral JAK1/2 inhibitor <a class="drug drug_general" data-topicid="118052" href="/d/drug information/118052.html" rel="external">baricitinib</a> (n = 60) or placebo (n = 31) [<a href="#rid50">50</a>]. After 48 weeks of therapy, stimulated mean C-peptide level was greater with baricitinib compared with placebo (median 0.65 versus 0.43 nmol/L/min, respectively). A1C, frequency of hypoglycemia, and the percentage of time spent in the target glucose range (70 to 180 mg/dL [3.9 to 10 mmol/L]) were not significantly different between groups.</p><p></p><p class="headingAnchor" id="H1256706530"><span class="h3">Lymphocyte-directed therapies</span><span class="headingEndMark"> — </span>Several B cell- or T cell-directed immunotherapies have proven effective for preserving insulin secretion in new-onset clinical (stage 3) type 1 diabetes.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Teplizumab</strong> – <a class="drug drug_general" data-topicid="140208" href="/d/drug information/140208.html" rel="external">Teplizumab</a> is an anti-CD3 monoclonal antibody that blocks activated T cells, has been tested in multiple trials in new-onset type 1 diabetes and, in the United States, is the only treatment approved for preclinical type 1 diabetes. (See <a class="local">'Teplizumab'</a> above.)</p><p></p><p class="bulletIndent1">Trials in patients with clinical (stage 3) type 1 diabetes have demonstrated that <a class="drug drug_general" data-topicid="140208" href="/d/drug information/140208.html" rel="external">teplizumab</a> therapy preserves insulin secretion [<a href="#rid51">51</a>]. Adverse effects in these trials included lymphopenia, rash, nausea/vomiting, liver transaminase elevation, and headache, similar to those seen in trials in participants with preclinical diabetes. Adverse events requiring permanent study drug discontinuation occurred in 14.3 and 3.7 percent of participants in teplizumab-treated and control groups, respectively. The most common of these were laboratory abnormalities, including liver enzyme elevations, neutropenia, and lymphopenia. (See <a class="local">'Efficacy and side effects'</a> above.)</p><p></p><p class="bulletIndent1">As examples of these trials:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In a preliminary trial in 24 individuals with newly diagnosed (within six weeks) type 1 diabetes, <a class="drug drug_general" data-topicid="140208" href="/d/drug information/140208.html" rel="external">teplizumab</a> preserved insulin secretory capacity compared with placebo [<a href="#rid52">52</a>]. A difference in beta cell function between groups remained evident two years after treatment [<a href="#rid53">53</a>]. In a subsequent trial, 52 individuals with newly diagnosed type 1 diabetes who were previously treated with teplizumab underwent a second 14-day course of teplizumab administered 12 months after the first course [<a href="#rid54">54</a>]. After two years of follow-up, teplizumab delayed C-peptide loss by 15.9 months compared with no treatment. In a post hoc analysis, predictors of treatment response included lower A1C and lower insulin use at baseline [<a href="#rid54">54</a>]. Seven years after treatment, responders to teplizumab therapy continued to exhibit higher stimulated C-peptide production and more favorable immune phenotypes [<a href="#rid55">55</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In a phase III trial in 516 individuals with newly diagnosed type 1 diabetes, participants were randomly assigned to one of four treatment arms: a full- or low-dose, single course of 14 daily <a class="drug drug_general" data-topicid="140208" href="/d/drug information/140208.html" rel="external">teplizumab</a> infusions; a full-dose, single course of six daily teplizumab infusions followed by eight daily placebo infusions; or a placebo arm (14 daily placebo infusions) [<a href="#rid56">56</a>]. All treatments were repeated after six months. The study did not meet its primary endpoint, a composite of clinical measures including A1C and daily insulin dose, rather than the more standard endpoint of stimulated C-peptide [<a href="#rid57">57</a>]. Nonetheless, post hoc analysis demonstrated benefit of a 14-day course of teplizumab relative to placebo in subgroups including individuals with greater C-peptide production, lower insulin use, lower A1C at baseline, and randomization close to time of diagnosis [<a href="#rid58">58</a>], suggesting that administration of drug early in clinical disease could be more effective.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In a phase III trial in children and adolescents with newly diagnosed (within six weeks) type 1 diabetes, participants were randomly assigned to two, 12-day courses of <a class="drug drug_general" data-topicid="140208" href="/d/drug information/140208.html" rel="external">teplizumab</a> (n = 217) or placebo (n = 111) [<a href="#rid59">59</a>]. At 78 weeks, teplizumab treatment preserved C-peptide production compared with placebo (least-squares mean difference in C-peptide AUC of 0.13 pmol/mL), and the rate of preserved C-peptide production (peak level ≥0.2 pmol/mL) was higher in the teplizumab group (94.9 versus 79.2 percent with placebo). The percentage of time spent in the target glucose range (70 to 180 mg/dL [3.9 to 10 mmol/L]) was not significantly different between groups (68.7 versus 64.6 percent with teplizumab and placebo, respectively). Mean daily insulin dose did not change in the teplizumab group (0.45 units/kg/day at baseline and 78 weeks) but increased numerically in the placebo group (0.38 and 0.6 units/kg/day at baseline and 78 weeks, respectively).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Rituximab</strong> – <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">Rituximab</a> is an anti-CD20 monoclonal antibody that destroys B cells. In a trial in 87 adults and children with new-onset type 1 diabetes, rituximab treatment resulted in a modestly higher stimulated C-peptide AUC than placebo (0.56 versus 0.47 pmol/mL, respectively) one year after treatment initiation [<a href="#rid60">60</a>]. Adverse effects of rituximab included infusion reactions and the expected decline in B cells [<a href="#rid60">60,61</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Abatacept</strong> – <a class="drug drug_general" data-topicid="8526" href="/d/drug information/8526.html" rel="external">Abatacept</a> is a cytotoxic T lymphocyte antigen 4 (CTLA4) immunoglobulin that blocks T cell costimulation. In a trial in 112 adults and children with new-onset type 1 diabetes, stimulated C-peptide AUC was 59 percent higher in the abatacept group than in the placebo group after two years of treatment [<a href="#rid62">62</a>]. Reported adverse events did not differ between the two groups [<a href="#rid62">62,63</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Sequential treatment regimens with </strong><strong>rituximab</strong><strong> followed by </strong><strong>abatacept</strong> – Post hoc analyses of trial data have suggested the possible synergistic benefit of sequential therapy with <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a> and <a class="drug drug_general" data-topicid="8526" href="/d/drug information/8526.html" rel="external">abatacept</a> [<a href="#rid64">64,65</a>]. In a proposed trial, treatment with rituximab will be followed by weekly subcutaneous injections of abatacept [<a href="#rid66">66</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Alefacept</strong> – Alefacept is an anti-CD2 therapy that generates anti-memory T cell effects. In a trial in 49 adolescents and adults with new-onset type 1 diabetes, alefacept treatment increased stimulated C-peptide AUC relative to placebo (0.015 versus -0.156 nmol/L, respectively) after one year of treatment [<a href="#rid67">67</a>]. Adverse events were similar in alefacept- and placebo-treated participants [<a href="#rid67">67,68</a>]. Early phase trials of siplizumab, an anti-CD2 monoclonal antibody similar to alefacept, are underway.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Antithymocyte globulin </strong>– Antithymocyte globulin (ATG), which depletes activated B cells and T cells, was tested in a trial in 89 adolescents and adults with new-onset type 1 diabetes that simultaneously tested combination therapy with ATG and granulocyte colony-stimulating factor (GCSF) [<a href="#rid42">42</a>]. ATG treatment led to a higher stimulated C-peptide AUC than placebo (0.646 versus 0.406 nmol/L, respectively), whereas combination therapy did not confer benefit. Stimulated C-peptide AUC remained significantly higher in ATG-treated individuals two years after randomization  (<a class="graphic graphic_figure graphicRef141629" href="/d/graphic/141629.html" rel="external">figure 4</a>) [<a href="#rid69">69</a>].</p><p></p><p class="headingAnchor" id="H918523647"><span class="h3">Cellular therapies</span><span class="headingEndMark"> — </span>Several trials have tested the infusion of cells intended to either regulate immune function or replace destroyed or dysfunctional beta cells. These therapies are designed to preserve or replace endogenous insulin secretion, respectively.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Autologous regulatory T cells </strong>– Peripheral infusion of autologous regulatory T cells has been tested as monotherapy or in combination with low dose IL-2 [<a href="#rid70">70-73</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dendritic cells</strong> – Antigen-specific dendritic cell treatments may promote tolerance of type 1 diabetes-specific antigens [<a href="#rid74">74,75</a>], and promising early studies have prompted further investigation.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Stem cells</strong> – Stem cells include pluripotent embryonic cells, multipotent mesenchymal cells, or induced pluripotent cells. Mesenchymal stem cells (MSC) possess immunoregulatory properties, lack immunogenicity, and secrete factors that enhance local tissue repair [<a href="#rid76">76</a>]. The capacity of MSCs to modify disease course in type 1 diabetes has been investigated in small trials [<a href="#rid77">77-79</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Allogeneic islet cell transplantation</strong> – Allogeneic islet cell transplantation can impart insulin independence and is an effective therapy for patients with severe hypoglycemia. Limitations include a limited supply of human islet cell donors, need for lifelong immunosuppression, and lower rates of insulin independence compared with whole pancreas transplant [<a href="#rid80">80-83</a>]. Islet cell encapsulation is a promising investigational strategy to protect the islet cells from rejection and thereby circumvent the need for lifelong immunosuppression. (See  <a class="medical medical_review" href="/d/html/1767.html" rel="external">"Pancreas and islet transplantation in diabetes mellitus", section on 'Islet transplantation'</a>.)</p><p></p><p class="headingAnchor" id="H106170565"><span class="h3">Beta cell support (eg, verapamil)</span><span class="headingEndMark"> — </span>While most disease-modifying therapies for type 1 diabetes have targeted immune-mediated beta cell destruction, other therapies provide direct beta cell support or reduce beta cell stress. These treatments may be used in combination with immunotherapy in future trials [<a href="#rid84">84</a>].</p><p>The following therapies are in development to provide beta cell support:</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="10043" href="/d/drug information/10043.html" rel="external">Verapamil</a> is a calcium channel blocker with a long record of clinical use in hypertension and tachycardia syndromes. Although verapamil is widely available and inexpensive, its off-label use in type 1 diabetes should be avoided, as additional safety and efficacy data are needed in this population.</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="10043" href="/d/drug information/10043.html" rel="external">Verapamil</a> reduces the expression of thioredoxin-interacting protein (TXNIP), which is toxic to beta cells. In a small trial in 32 adults with new-onset type 1 diabetes, verapamil treatment led to higher stimulated C-peptide AUC at 3 and 12 months compared with placebo [<a href="#rid85">85</a>].</p><p></p><p class="bulletIndent1">A subsequent trial in 88 children and adolescents with newly diagnosed type 1 diabetes (aged 7 to 17 years, mean time from diagnosis 24 days) tested <a class="drug drug_general" data-topicid="10043" href="/d/drug information/10043.html" rel="external">verapamil</a> in conjunction with partially automated (hybrid closed-loop) insulin therapy. At one year, C-peptide AUC was 30 percent higher in participants treated with verapamil (0.65 versus 0.44 pmol/mL with placebo, adjusted between-group difference 0.14 pmol/mL), whereas intensive insulin therapy provided no additional benefit [<a href="#rid86">86,87</a>]. In the verapamil group, three participants developed abnormal electrocardiogram findings, including first- and second-degree heart block, and hypotension occurred in one participant. A European network is testing verapamil in a trial in adults with newly diagnosed type 1 diabetes.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Tyrosine kinase inhibitors [<a href="#rid88">88</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Difluoromethylornithine<strong> </strong>(DMFO).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Tauroursodeoxycholic acid.</p><p></p><p class="headingAnchor" id="H2278359036"><span class="h3">Insulin antigen therapy</span><span class="headingEndMark"> — </span>Anti-insulin antibodies often appear early in islet autoimmunity [<a href="#rid89">89,90</a>], making insulin, its precursors (eg, pre-proinsulin and proinsulin), and insulin components (eg, B-chain) attractive targets for antigen therapy. Most trials testing insulin in new-onset or longer standing type 1 diabetes have not demonstrated endogenous insulin preservation, but several have identified promising markers of therapeutic immune modulation, prompting further study [<a href="#rid91">91-94</a>]. Ongoing trials in new-onset type 1 diabetes will deliver insulin in a modified fashion, for example, as a component of a plasmid deoxyribonucleic acid (DNA), via genetically modified bacteria, or as a nanoparticle to augment immune system exposure to insulin antigens. Endpoints of these early studies include safety and detection of a therapeutic immune signal.</p><p class="headingAnchor" id="H792637606"><span class="h2">Therapies without demonstrated benefit after clinical diagnosis</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Microbiome modulation/probiotics</strong> – Some studies have suggested that the fecal microbiome changes after diagnosis of type 1 diabetes [<a href="#rid95">95</a>]. However, whether this apparent dysbiosis contributes to disease pathogenesis is unknown, as are the possible therapeutic effects of manipulating the fecal microbiome (eg, through transplant or probiotic supplementation). In trials in individuals with new-onset type 1 diabetes, neither fecal transplant nor prebiotic or probiotic supplementation have modified disease course [<a href="#rid96">96-101</a>], but this remains an area of active investigation.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cyclosporine</strong> – <a class="drug drug_general" data-topicid="9217" href="/d/drug information/9217.html" rel="external">Cyclosporine</a> was one of the earliest anti-lymphocyte agents tested to induce remission in new-onset type 1 diabetes. Although cyclosporine induced remission in children with newly diagnosed type 1 diabetes, treatment conferred kidney and other toxicities [<a href="#rid102">102-104</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Azathioprine</strong> – The antipurine agent <a class="drug drug_general" data-topicid="9026" href="/d/drug information/9026.html" rel="external">azathioprine</a> was tested in new-onset type 1 diabetes both as monotherapy and in combination with <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a>. Like <a class="drug drug_general" data-topicid="9217" href="/d/drug information/9217.html" rel="external">cyclosporine</a>, azathioprine caused significant side effects, and it failed to preserve endogenous insulin secretion [<a href="#rid105">105-107</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mycophenolate</strong><strong> mofetil</strong> – In a trial in 126 individuals with newly diagnosed type 1 diabetes (within three months), treatment with the antipurine agent <a class="drug drug_general" data-topicid="9670" href="/d/drug information/9670.html" rel="external">mycophenolate</a> mofetil, either as monotherapy or combined with anti-IL-2 therapy, did not affect stimulated C-peptide AUC at two years [<a href="#rid108">108</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Anti-IL-1, anti-IL-6, and anti-IL-8 therapies</strong> – To date, therapies that inhibit IL-1, IL-6, and IL-8 have proven ineffective for preserving insulin secretion in newly diagnosed type 1 diabetes [<a href="#rid109">109-111</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Anti-IL-21 and GLP-1 receptor agonist combination therapy</strong> – In a trial in 308 adults with newly diagnosed type 1 diabetes, participants were randomly assigned to treatment with placebo, anti-IL-21 therapy, the glucagon-like peptide 1 (GLP-1) receptor agonist <a class="drug drug_general" data-topicid="9522" href="/d/drug information/9522.html" rel="external">liraglutide</a>, or both liraglutide and anti-IL-21 therapy [<a href="#rid112">112</a>]. After one year of treatment, only combination therapy preserved C-peptide production relative to placebo. However, six months after treatment cessation, both liraglutide groups tended toward greater loss of insulin secretion compared with the placebo and anti-IL-21 groups, suggesting that the initial benefit of GLP-1 agonist therapy may have been related to its known augmentation of insulin secretion, rather than to modification of the underlying disease.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Early intensive insulin therapy</strong> – Several trials have investigated the introduction of early, intensive insulin therapy in new-onset type 1 diabetes. While an early study demonstrated a benefit for preservation of C-peptide, subsequent trials testing this intervention have been negative [<a href="#rid87">87,113-115</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Glutamic acid decarboxylase 65</strong> – Glutamic acid decarboxylase 65 (GAD-65) is an enzyme essential for the formation of gamma aminobutyric acid (GABA), an inhibitory neurotransmitter that can be detected in neural and neuroendocrine cells including islet cells. GAD-65 treatment has been tested in multiple new-onset type 1 diabetes trials but overall has shown no benefit for preserving insulin secretion [<a href="#rid116">116-118</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hematopoietic stem cell transplantation</strong> – Autologous hematopoietic stem cell transplantation (HSCT) entails ex vivo expansion of pluripotent stem cells with subsequent infusion into a patient who has undergone nonmyeloablative chemotherapeutic conditioning. Although therapy confers a high rate of insulin independence, the conditioning component of HSCT imparts significant risks, including life-threatening bone marrow aplasia and sepsis [<a href="#rid119">119</a>]. These risks render HSCT unlikely to be useful in type 1 diabetes.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dietary modification or supplementation</strong> – No<em> </em>dietary supplements have shown efficacy for preserving insulin secretion in new-onset type 1 diabetes, although high-quality studies are limited. Dietary approaches that have been investigated include avoidance of dietary gluten, vitamin D supplementation, and omega-3 fatty acid supplementation, none of which has demonstrated benefit after clinical diagnosis [<a href="#rid120">120-123</a>].</p><p></p><p class="headingAnchor" id="H3551707799"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/d/html/15401.html" rel="external">"Patient education: Type 1 diabetes (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/d/html/1736.html" rel="external">"Patient education: Type 1 diabetes: Overview (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H1195737235"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Need for disease-modifying therapies</strong> – Most individuals living with type 1 diabetes mellitus do not meet the therapeutic targets that are associated with a lower risk of long-term complications. Type 1 diabetes also exacts an emotional, cognitive, and financial toll on individuals, families, and society and continues to limit life expectancy. Therefore, alternative approaches that modify the natural history of disease could dramatically improve both quality of life and health outcomes for individuals with type 1 diabetes. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Preclinical progression</strong> – Type 1 diabetes has a long preclinical period with well-defined stages of disease progression  (<a class="graphic graphic_table graphicRef141622" href="/d/graphic/141622.html" rel="external">table 1</a>), affording an opportunity to intervene with disease-modifying therapies. Virtually all individuals with preclinical disease progress to clinical type 1 diabetes. These stages are as follows (see <a class="local">'Stages of type 1 diabetes'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Stage 1</strong> – Stage 1 diabetes is an asymptomatic period defined by seroconversion with the presence of at least two diabetes-related autoantibodies but preserved normoglycemia.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Stage 2</strong> – Stage 2 diabetes is characterized by asymptomatic progression to dysglycemia.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Stage 3</strong> – Stage 3 diabetes is the onset of clinical disease and is defined by glycemic criteria. Individuals with stage 3 diabetes usually but not uniformly have diabetes-related symptoms.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Teplizumab</strong><strong> therapy</strong> – <a class="drug drug_general" data-topicid="140208" href="/d/drug information/140208.html" rel="external">Teplizumab</a>, a humanized anti-CD3 monoclonal antibody, is the only therapy with regulatory approval in the United States for delaying the onset of clinical type 1 diabetes in individuals with preclinical disease. (See <a class="local">'Teplizumab'</a> above.)</p><p></p><p class="bulletIndent1">In the United States, <a class="drug drug_general" data-topicid="140208" href="/d/drug information/140208.html" rel="external">teplizumab</a> is approved for individuals aged 8 years and older who have stage 2 diabetes (≥2 diabetes-related autoantibodies and dysglycemia)  (<a class="graphic graphic_table graphicRef141622" href="/d/graphic/141622.html" rel="external">table 1</a>) and is administered as a single 14-day course of daily intravenous infusions. The implementation of teplizumab in clinical practice is evolving and varies regionally. For individuals who meet criteria for teplizumab therapy, the choice to initiate treatment should be individualized based on patient and family preferences and the availability of infrastructure to support treatment infusions.</p><p></p><p class="bulletIndent1">Adverse effects include transient lymphopenia, rash, anemia, and fever.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other strategies to prevent or delay type 1 diabetes onset</strong> – Other immune-modulating therapies are under investigation to prevent or delay the onset of type 1 diabetes in individuals at high risk for developing the disease. (See <a class="local">'Therapies in development for preclinical disease'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Benefit of preserved insulin secretion after diagnosis</strong> – Preservation of endogenous insulin secretion after the clinical diagnosis of type 1 diabetes is associated with enduring benefits, including reduced risks of microvascular complications and severe hypoglycemia. (See <a class="local">'Clinical benefits of preserved insulin secretion'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Strategies to preserve beta cell function after diagnosis</strong> – Many therapeutic strategies have been investigated for preserving beta cell function after the clinical diagnosis of type 1 diabetes. Although no immune-modulating therapies are approved for use in clinical (stage 3) type 1 diabetes, several have demonstrated a reasonable risk profile and the capacity to modify the underlying disease and preserve insulin secretion. (See <a class="local">'Promising investigational therapies to preserve insulin secretion'</a> above.)</p><p></p><p class="headingAnchor" id="H1420299750"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges David McCulloch, MD, who contributed to earlier versions of this topic review.</p><p>The UpToDate editorial staff also acknowledges Massimo Pietropaolo, MD (deceased), who contributed to earlier versions of this topic.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Miller KM, Foster NC, Beck RW, et al. Current state of type 1 diabetes treatment in the U.S.: updated data from the T1D Exchange clinic registry. Diabetes Care 2015; 38:971.</a></li><li><a class="nounderline abstract_t">Foster NC, Beck RW, Miller KM, et al. State of Type 1 Diabetes Management and Outcomes from the T1D Exchange in 2016-2018. Diabetes Technol Ther 2019; 21:66.</a></li><li><a class="nounderline abstract_t">Chua KP, Lee JM, Conti RM. Out-of-Pocket Spending for Insulin, Diabetes-Related Supplies, and Other Health Care Services Among Privately Insured US Patients With Type 1 Diabetes. JAMA Intern Med 2020; 180:1012.</a></li><li><a class="nounderline abstract_t">Sussman M, Benner J, Haller MJ, et al. Estimated Lifetime Economic Burden of Type 1 Diabetes. Diabetes Technol Ther 2020; 22:121.</a></li><li><a class="nounderline abstract_t">Maffi P, Secchi A. The Burden of Diabetes: Emerging Data. Dev Ophthalmol 2017; 60:1.</a></li><li><a class="nounderline abstract_t">Fisher L, Hessler D, Polonsky W, et al. Diabetes distress in adults with type 1 diabetes: Prevalence, incidence and change over time. J Diabetes Complications 2016; 30:1123.</a></li><li><a class="nounderline abstract_t">Evans-Molina C, Sims EK, DiMeglio LA, et al. β Cell dysfunction exists more than 5 years before type 1 diabetes diagnosis. JCI Insight 2018; 3.</a></li><li><a class="nounderline abstract_t">Sosenko JM, Skyler JS, Beam CA, et al. Acceleration of the loss of the first-phase insulin response during the progression to type 1 diabetes in diabetes prevention trial-type 1 participants. Diabetes 2013; 62:4179.</a></li><li><a class="nounderline abstract_t">Bogun MM, Bundy BN, Goland RS, Greenbaum CJ. C-Peptide Levels in Subjects Followed Longitudinally Before and After Type 1 Diabetes Diagnosis in TrialNet. Diabetes Care 2020; 43:1836.</a></li><li><a class="nounderline abstract_t">Greenbaum CJ, Beam CA, Boulware D, et al. Fall in C-peptide during first 2 years from diagnosis: evidence of at least two distinct phases from composite Type 1 Diabetes TrialNet data. Diabetes 2012; 61:2066.</a></li><li><a class="nounderline abstract_t">Herold KC, Bundy BN, Long SA, et al. An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes. N Engl J Med 2019; 381:603.</a></li><li><a class="nounderline abstract_t">Sims EK, Bundy BN, Stier K, et al. Teplizumab improves and stabilizes beta cell function in antibody-positive high-risk individuals. Sci Transl Med 2021; 13.</a></li><li class="breakAll">STOP-T1D Low-Dose (ATG). Available at: https://clinicaltrials.gov/ct2/show/NCT04291703 (Accessed on March 07, 2023).</li><li><a class="nounderline abstract_t">Russell WE, Bundy BN, Anderson MS, et al. Abatacept for Delay of Type 1 Diabetes Progression in Stage 1 Relatives at Risk: A Randomized, Double-Masked, Controlled Trial. Diabetes Care 2023; 46:1005.</a></li><li class="breakAll">Hydroxychloroquine in Individuals At-risk for Type 1 Diabetes Mellitus. Available at: https://www.clinicaltrials.gov/ct2/show/NCT03428945 (Accessed on March 07, 2023).</li><li><a class="nounderline abstract_t">Libman I, Bingley PJ, Becker D, et al. Hydroxychloroquine in Stage 1 Type 1 Diabetes. Diabetes Care 2023; 46:2035.</a></li><li><a class="nounderline abstract_t">Skyler JS, Krischer JP, Wolfsdorf J, et al. Effects of oral insulin in relatives of patients with type 1 diabetes: The Diabetes Prevention Trial--Type 1. Diabetes Care 2005; 28:1068.</a></li><li><a class="nounderline abstract_t">Skyler JS, Type 1 Diabetes TrialNet Study Group. Update on worldwide efforts to prevent type 1 diabetes. Ann N Y Acad Sci 2008; 1150:190.</a></li><li><a class="nounderline abstract_t">Vehik K, Cuthbertson D, Ruhlig H, et al. Long-term outcome of individuals treated with oral insulin: diabetes prevention trial-type 1 (DPT-1) oral insulin trial. Diabetes Care 2011; 34:1585.</a></li><li><a class="nounderline abstract_t">Writing Committee for the Type 1 Diabetes TrialNet Oral Insulin Study Group, Krischer JP, Schatz DA, et al. Effect of Oral Insulin on Prevention of Diabetes in Relatives of Patients With Type 1 Diabetes: A Randomized Clinical Trial. JAMA 2017; 318:1891.</a></li><li><a class="nounderline abstract_t">Bonifacio E, Ziegler AG, Klingensmith G, et al. Effects of high-dose oral insulin on immune responses in children at high risk for type 1 diabetes: the Pre-POINT randomized clinical trial. JAMA 2015; 313:1541.</a></li><li><a class="nounderline abstract_t">Ziegler AG, Achenbach P, Berner R, et al. Oral insulin therapy for primary prevention of type 1 diabetes in infants with high genetic risk: the GPPAD-POInT (global platform for the prevention of autoimmune diabetes primary oral insulin trial) study protocol. BMJ Open 2019; 9:e028578.</a></li><li><a class="nounderline abstract_t">Greenbaum CJ, McCulloch-Olson M, Chiu HK, et al. Parenteral insulin suppresses T cell proliferation to islet antigens. Pediatr Diabetes 2011; 12:150.</a></li><li><a class="nounderline abstract_t">Näntö-Salonen K, Kupila A, Simell S, et al. Nasal insulin to prevent type 1 diabetes in children with HLA genotypes and autoantibodies conferring increased risk of disease: a double-blind, randomised controlled trial. Lancet 2008; 372:1746.</a></li><li class="breakAll">Trial of Intranasal Insulin in Children and Young Adults at Risk of Type 1 Diabetes (INITII). Available at: https://clinicaltrials.gov/ct2/show/NCT00336674 (Accessed on February 07, 2023).</li><li><a class="nounderline abstract_t">Gale EA, Bingley PJ, Emmett CL, et al. European Nicotinamide Diabetes Intervention Trial (ENDIT): a randomised controlled trial of intervention before the onset of type 1 diabetes. Lancet 2004; 363:925.</a></li><li><a class="nounderline abstract_t">Davis AK, DuBose SN, Haller MJ, et al. Prevalence of detectable C-Peptide according to age at diagnosis and duration of type 1 diabetes. Diabetes Care 2015; 38:476.</a></li><li><a class="nounderline abstract_t">Oram RA, McDonald TJ, Shields BM, et al. Most people with long-duration type 1 diabetes in a large population-based study are insulin microsecretors. Diabetes Care 2015; 38:323.</a></li><li><a class="nounderline abstract_t">Keenan HA, Sun JK, Levine J, et al. Residual insulin production and pancreatic ß-cell turnover after 50 years of diabetes: Joslin Medalist Study. Diabetes 2010; 59:2846.</a></li><li><a class="nounderline abstract_t">Yu MG, Keenan HA, Shah HS, et al. Residual β cell function and monogenic variants in long-duration type 1 diabetes patients. J Clin Invest 2019; 129:3252.</a></li><li><a class="nounderline abstract_t">Effect of intensive therapy on residual beta-cell function in patients with type 1 diabetes in the diabetes control and complications trial. A randomized, controlled trial. The Diabetes Control and Complications Trial Research Group. Ann Intern Med 1998; 128:517.</a></li><li><a class="nounderline abstract_t">Bain SC, Gill GV, Dyer PH, et al. Characteristics of Type 1 diabetes of over 50 years duration (the Golden Years Cohort). Diabet Med 2003; 20:808.</a></li><li><a class="nounderline abstract_t">Sun JK, Keenan HA, Cavallerano JD, et al. Protection from retinopathy and other complications in patients with type 1 diabetes of extreme duration: the joslin 50-year medalist study. Diabetes Care 2011; 34:968.</a></li><li><a class="nounderline abstract_t">Diabetes Control and Complications Trial Research Group, Nathan DM, Genuth S, et al. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329:977.</a></li><li><a class="nounderline abstract_t">Pinckney A, Rigby MR, Keyes-Elstein L, et al. Correlation Among Hypoglycemia, Glycemic Variability, and C-Peptide Preservation After Alefacept Therapy in Patients with Type 1 Diabetes Mellitus: Analysis of Data from the Immune Tolerance Network T1DAL Trial. Clin Ther 2016; 38:1327.</a></li><li><a class="nounderline abstract_t">Brooks AM, Oram R, Home P, et al. Demonstration of an intrinsic relationship between endogenous C-peptide concentration and determinants of glycemic control in type 1 diabetes following islet transplantation. Diabetes Care 2015; 38:105.</a></li><li><a class="nounderline abstract_t">Steffes MW, Sibley S, Jackson M, Thomas W. Beta-cell function and the development of diabetes-related complications in the diabetes control and complications trial. Diabetes Care 2003; 26:832.</a></li><li><a class="nounderline abstract_t">Baidal DA, Ballou CM, Rickels MR, et al. Predictive Value of C-Peptide Measures for Clinical Outcomes of β-Cell Replacement Therapy in Type 1 Diabetes: Report From the Collaborative Islet Transplant Registry (CITR). Diabetes Care 2023; 46:697.</a></li><li><a class="nounderline abstract_t">Lachin JM, McGee P, Palmer JP, DCCT/EDIC Research Group. Impact of C-peptide preservation on metabolic and clinical outcomes in the Diabetes Control and Complications Trial. Diabetes 2014; 63:739.</a></li><li><a class="nounderline abstract_t">Jeyam A, Colhoun H, McGurnaghan S, et al. Clinical Impact of Residual C-Peptide Secretion in Type 1 Diabetes on Glycemia and Microvascular Complications. Diabetes Care 2021; 44:390.</a></li><li><a class="nounderline abstract_t">Vantyghem MC, Raverdy V, Balavoine AS, et al. Continuous glucose monitoring after islet transplantation in type 1 diabetes: an excellent graft function (β-score greater than 7) Is required to abrogate hyperglycemia, whereas a minimal function is necessary to suppress severe hypoglycemia (β-score greater than 3). J Clin Endocrinol Metab 2012; 97:E2078.</a></li><li><a class="nounderline abstract_t">Haller MJ, Schatz DA, Skyler JS, et al. Low-Dose Anti-Thymocyte Globulin (ATG) Preserves β-Cell Function and Improves HbA1c in New-Onset Type 1 Diabetes. Diabetes Care 2018; 41:1917.</a></li><li><a class="nounderline abstract_t">Mastrandrea L, Yu J, Behrens T, et al. Etanercept treatment in children with new-onset type 1 diabetes: pilot randomized, placebo-controlled, double-blind study. Diabetes Care 2009; 32:1244.</a></li><li><a class="nounderline abstract_t">Quattrin T, Haller MJ, Steck AK, et al. Golimumab and Beta-Cell Function in Youth with New-Onset Type 1 Diabetes. N Engl J Med 2020; 383:2007.</a></li><li><a class="nounderline abstract_t">Rigby MR, Hayes B, Li Y, et al. Two-Year Follow-up From the T1GER Study: Continued Off-Therapy Metabolic Improvements in Children and Young Adults With New-Onset T1D Treated With Golimumab and Characterization of Responders. Diabetes Care 2023; 46:561.</a></li><li><a class="nounderline abstract_t">Long SA, Cerosaletti K, Bollyky PL, et al. Defects in IL-2R signaling contribute to diminished maintenance of FOXP3 expression in CD4(+)CD25(+) regulatory T-cells of type 1 diabetic subjects. Diabetes 2010; 59:407.</a></li><li><a class="nounderline abstract_t">Tang Q, Adams JY, Penaranda C, et al. Central role of defective interleukin-2 production in the triggering of islet autoimmune destruction. Immunity 2008; 28:687.</a></li><li><a class="nounderline abstract_t">Long SA, Rieck M, Sanda S, et al. Rapamycin/IL-2 combination therapy in patients with type 1 diabetes augments Tregs yet transiently impairs β-cell function. Diabetes 2012; 61:2340.</a></li><li><a class="nounderline abstract_t">Trivedi PM, Graham KL, Scott NA, et al. Repurposed JAK1/JAK2 Inhibitor Reverses Established Autoimmune Insulitis in NOD Mice. Diabetes 2017; 66:1650.</a></li><li><a class="nounderline abstract_t">Waibel M, Wentworth JM, So M, et al. Baricitinib and β-Cell Function in Patients with New-Onset Type 1 Diabetes. N Engl J Med 2023; 389:2140.</a></li><li><a class="nounderline abstract_t">Herold KC, Gitelman SE, Gottlieb PA, et al. Teplizumab: A Disease-Modifying Therapy for Type 1 Diabetes That Preserves β-Cell Function. Diabetes Care 2023; 46:1848.</a></li><li><a class="nounderline abstract_t">Herold KC, Hagopian W, Auger JA, et al. Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N Engl J Med 2002; 346:1692.</a></li><li><a class="nounderline abstract_t">Herold KC, Gitelman SE, Masharani U, et al. A single course of anti-CD3 monoclonal antibody hOKT3gamma1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes. Diabetes 2005; 54:1763.</a></li><li><a class="nounderline abstract_t">Herold KC, Gitelman SE, Ehlers MR, et al. Teplizumab (anti-CD3 mAb) treatment preserves C-peptide responses in patients with new-onset type 1 diabetes in a randomized controlled trial: metabolic and immunologic features at baseline identify a subgroup of responders. Diabetes 2013; 62:3766.</a></li><li><a class="nounderline abstract_t">Perdigoto AL, Preston-Hurlburt P, Clark P, et al. Treatment of type 1 diabetes with teplizumab: clinical and immunological follow-up after 7 years from diagnosis. Diabetologia 2019; 62:655.</a></li><li><a class="nounderline abstract_t">Sherry N, Hagopian W, Ludvigsson J, et al. Teplizumab for treatment of type 1 diabetes (Protégé study): 1-year results from a randomised, placebo-controlled trial. Lancet 2011; 378:487.</a></li><li><a class="nounderline abstract_t">Palmer JP, Fleming GA, Greenbaum CJ, et al. C-peptide is the appropriate outcome measure for type 1 diabetes clinical trials to preserve beta-cell function: report of an ADA workshop, 21-22 October 2001. Diabetes 2004; 53:250.</a></li><li><a class="nounderline abstract_t">Hagopian W, Ferry RJ Jr, Sherry N, et al. Teplizumab preserves C-peptide in recent-onset type 1 diabetes: two-year results from the randomized, placebo-controlled Protégé trial. Diabetes 2013; 62:3901.</a></li><li><a class="nounderline abstract_t">Ramos EL, Dayan CM, Chatenoud L, et al. Teplizumab and β-Cell Function in Newly Diagnosed Type 1 Diabetes. N Engl J Med 2023; 389:2151.</a></li><li><a class="nounderline abstract_t">Pescovitz MD, Greenbaum CJ, Krause-Steinrauf H, et al. Rituximab, B-lymphocyte depletion, and preservation of beta-cell function. N Engl J Med 2009; 361:2143.</a></li><li><a class="nounderline abstract_t">Pescovitz MD, Greenbaum CJ, Bundy B, et al. B-lymphocyte depletion with rituximab and β-cell function: two-year results. Diabetes Care 2014; 37:453.</a></li><li><a class="nounderline abstract_t">Orban T, Bundy B, Becker DJ, et al. Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial. Lancet 2011; 378:412.</a></li><li><a class="nounderline abstract_t">Orban T, Bundy B, Becker DJ, et al. Costimulation modulation with abatacept in patients with recent-onset type 1 diabetes: follow-up 1 year after cessation of treatment. Diabetes Care 2014; 37:1069.</a></li><li><a class="nounderline abstract_t">Linsley PS, Greenbaum CJ, Speake C, et al. B lymphocyte alterations accompany abatacept resistance in new-onset type 1 diabetes. JCI Insight 2019; 4.</a></li><li><a class="nounderline abstract_t">Linsley PS, Greenbaum CJ, Rosasco M, et al. Elevated T cell levels in peripheral blood predict poor clinical response following rituximab treatment in new-onset type 1 diabetes. Genes Immun 2019; 20:293.</a></li><li class="breakAll">Rituximab and Abatacept for Prevention or Reversal of Type 1 Diabetes. Available at: https://clinicaltrials.gov/ct2/show/NCT03929601 (Accessed on March 07, 2023).</li><li><a class="nounderline abstract_t">Rigby MR, DiMeglio LA, Rendell MS, et al. Targeting of memory T cells with alefacept in new-onset type 1 diabetes (T1DAL study): 12 month results of a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Diabetes Endocrinol 2013; 1:284.</a></li><li><a class="nounderline abstract_t">Rigby MR, Harris KM, Pinckney A, et al. Alefacept provides sustained clinical and immunological effects in new-onset type 1 diabetes patients. J Clin Invest 2015; 125:3285.</a></li><li><a class="nounderline abstract_t">Haller MJ, Long SA, Blanchfield JL, et al. Low-Dose Anti-Thymocyte Globulin Preserves C-Peptide, Reduces HbA1c, and Increases Regulatory to Conventional T-Cell Ratios in New-Onset Type 1 Diabetes: Two-Year Clinical Trial Data. Diabetes 2019; 68:1267.</a></li><li><a class="nounderline abstract_t">Bluestone JA, Buckner JH, Fitch M, et al. Type 1 diabetes immunotherapy using polyclonal regulatory T cells. Sci Transl Med 2015; 7:315ra189.</a></li><li><a class="nounderline abstract_t">Marek-Trzonkowska N, Myśliwiec M, Dobyszuk A, et al. Therapy of type 1 diabetes with CD4(+)CD25(high)CD127-regulatory T cells prolongs survival of pancreatic islets - results of one year follow-up. Clin Immunol 2014; 153:23.</a></li><li><a class="nounderline abstract_t">Marek-Trzonkowska N, Mysliwiec M, Dobyszuk A, et al. Administration of CD4+CD25highCD127- regulatory T cells preserves β-cell function in type 1 diabetes in children. Diabetes Care 2012; 35:1817.</a></li><li><a class="nounderline abstract_t">Dong S, Hiam-Galvez KJ, Mowery CT, et al. The effect of low-dose IL-2 and Treg adoptive cell therapy in patients with type 1 diabetes. JCI Insight 2021; 6.</a></li><li><a class="nounderline abstract_t">Khan FU, Khongorzul P, Raki AA, et al. Dendritic Cells and Their Immunotherapeutic Potential for Treating Type 1 Diabetes. Int J Mol Sci 2022; 23.</a></li><li><a class="nounderline abstract_t">Giannoukakis N, Phillips B, Finegold D, et al. Phase I (safety) study of autologous tolerogenic dendritic cells in type 1 diabetic patients. Diabetes Care 2011; 34:2026.</a></li><li><a class="nounderline abstract_t">Moreira A, Kahlenberg S, Hornsby P. Therapeutic potential of mesenchymal stem cells for diabetes. J Mol Endocrinol 2017; 59:R109.</a></li><li><a class="nounderline abstract_t">Hu J, Yu X, Wang Z, et al. Long term effects of the implantation of Wharton's jelly-derived mesenchymal stem cells from the umbilical cord for newly-onset type 1 diabetes mellitus. Endocr J 2013; 60:347.</a></li><li><a class="nounderline abstract_t">Carlsson PO, Schwarcz E, Korsgren O, Le Blanc K. Preserved β-cell function in type 1 diabetes by mesenchymal stromal cells. Diabetes 2015; 64:587.</a></li><li><a class="nounderline abstract_t">Izadi M, Sadr Hashemi Nejad A, Moazenchi M, et al. Mesenchymal stem cell transplantation in newly diagnosed type-1 diabetes patients: a phase I/II randomized placebo-controlled clinical trial. Stem Cell Res Ther 2022; 13:264.</a></li><li><a class="nounderline abstract_t">Wisel SA, Braun HJ, Stock PG. Current outcomes in islet versus solid organ pancreas transplant for β-cell replacement in type 1 diabetes. Curr Opin Organ Transplant 2016; 21:399.</a></li><li><a class="nounderline abstract_t">Carlsson PO, Espes D, Sedigh A, et al. Transplantation of macroencapsulated human islets within the bioartificial pancreas βAir to patients with type 1 diabetes mellitus. Am J Transplant 2018; 18:1735.</a></li><li><a class="nounderline abstract_t">Tomei AA, Villa C, Ricordi C. Development of an encapsulated stem cell-based therapy for diabetes. Expert Opin Biol Ther 2015; 15:1321.</a></li><li><a class="nounderline abstract_t">Wan XX, Zhang DY, Khan MA, et al. Stem Cell Transplantation in the Treatment of Type 1 Diabetes Mellitus: From Insulin Replacement to Beta-Cell Replacement. Front Endocrinol (Lausanne) 2022; 13:859638.</a></li><li><a class="nounderline abstract_t">Sims EK, Mirmira RG, Evans-Molina C. The role of beta-cell dysfunction in early type 1 diabetes. Curr Opin Endocrinol Diabetes Obes 2020; 27:215.</a></li><li><a class="nounderline abstract_t">Ovalle F, Grimes T, Xu G, et al. Verapamil and beta cell function in adults with recent-onset type 1 diabetes. Nat Med 2018; 24:1108.</a></li><li><a class="nounderline abstract_t">Forlenza GP, McVean J, Beck RW, et al. Effect of Verapamil on Pancreatic Beta Cell Function in Newly Diagnosed Pediatric Type 1 Diabetes: A Randomized Clinical Trial. JAMA 2023; 329:990.</a></li><li><a class="nounderline abstract_t">McVean J, Forlenza GP, Beck RW, et al. Effect of Tight Glycemic Control on Pancreatic Beta Cell Function in Newly Diagnosed Pediatric Type 1 Diabetes: A Randomized Clinical Trial. JAMA 2023; 329:980.</a></li><li><a class="nounderline abstract_t">Gitelman SE, Bundy BN, Ferrannini E, et al. Imatinib therapy for patients with recent-onset type 1 diabetes: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Diabetes Endocrinol 2021; 9:502.</a></li><li><a class="nounderline abstract_t">Krischer JP, Lynch KF, Schatz DA, et al. The 6 year incidence of diabetes-associated autoantibodies in genetically at-risk children: the TEDDY study. Diabetologia 2015; 58:980.</a></li><li><a class="nounderline abstract_t">Ilonen J, Hammais A, Laine AP, et al. Patterns of β-cell autoantibody appearance and genetic associations during the first years of life. Diabetes 2013; 62:3636.</a></li><li><a class="nounderline abstract_t">Pozzilli P, Pitocco D, Visalli N, et al. No effect of oral insulin on residual beta-cell function in recent-onset type I diabetes (the IMDIAB VII). IMDIAB Group. Diabetologia 2000; 43:1000.</a></li><li><a class="nounderline abstract_t">Walter M, Philotheou A, Bonnici F, et al. No effect of the altered peptide ligand NBI-6024 on beta-cell residual function and insulin needs in new-onset type 1 diabetes. Diabetes Care 2009; 32:2036.</a></li><li><a class="nounderline abstract_t">Thrower SL, James L, Hall W, et al. Proinsulin peptide immunotherapy in type 1 diabetes: report of a first-in-man Phase I safety study. Clin Exp Immunol 2009; 155:156.</a></li><li><a class="nounderline abstract_t">Orban T, Farkas K, Jalahej H, et al. Autoantigen-specific regulatory T cells induced in patients with type 1 diabetes mellitus by insulin B-chain immunotherapy. J Autoimmun 2010; 34:408.</a></li><li><a class="nounderline abstract_t">de Goffau MC, Luopajärvi K, Knip M, et al. Fecal microbiota composition differs between children with β-cell autoimmunity and those without. Diabetes 2013; 62:1238.</a></li><li><a class="nounderline abstract_t">de Groot P, Nikolic T, Pellegrini S, et al. Faecal microbiota transplantation halts progression of human new-onset type 1 diabetes in a randomised controlled trial. Gut 2021; 70:92.</a></li><li><a class="nounderline abstract_t">Wang CH, Yen HR, Lu WL, et al. Adjuvant Probiotics of Lactobacillus salivarius subsp. salicinius AP-32, L. johnsonii MH-68, and Bifidobacterium animalis subsp. lactis CP-9 Attenuate Glycemic Levels and Inflammatory Cytokines in Patients With Type 1 Diabetes Mellitus. Front Endocrinol (Lausanne) 2022; 13:754401.</a></li><li><a class="nounderline abstract_t">Kumar S, Kumar R, Rohilla L, et al. A high potency multi-strain probiotic improves glycemic control in children with new-onset type 1 diabetes mellitus: A randomized, double-blind, and placebo-controlled pilot study. Pediatr Diabetes 2021; 22:1014.</a></li><li><a class="nounderline abstract_t">Groele L, Szajewska H, Szalecki M, et al. Lack of effect of Lactobacillus rhamnosus GG and Bifidobacterium lactis Bb12 on beta-cell function in children with newly diagnosed type 1 diabetes: a randomised controlled trial. BMJ Open Diabetes Res Care 2021; 9.</a></li><li><a class="nounderline abstract_t">Savilahti E, Härkönen T, Savilahti EM, et al. Probiotic intervention in infancy is not associated with development of beta cell autoimmunity and type 1 diabetes. Diabetologia 2018; 61:2668.</a></li><li><a class="nounderline abstract_t">Ho J, Nicolucci AC, Virtanen H, et al. Effect of Prebiotic on Microbiota, Intestinal Permeability, and Glycemic Control in Children With Type 1 Diabetes. J Clin Endocrinol Metab 2019; 104:4427.</a></li><li><a class="nounderline abstract_t">Bougneres PF, Carel JC, Castano L, et al. Factors associated with early remission of type I diabetes in children treated with cyclosporine. N Engl J Med 1988; 318:663.</a></li><li><a class="nounderline abstract_t">Cyclosporin-induced remission of IDDM after early intervention. Association of 1 yr of cyclosporin treatment with enhanced insulin secretion. The Canadian-European Randomized Control Trial Group. Diabetes 1988; 37:1574.</a></li><li><a class="nounderline abstract_t">Bougnères PF, Landais P, Boisson C, et al. Limited duration of remission of insulin dependency in children with recent overt type I diabetes treated with low-dose cyclosporin. Diabetes 1990; 39:1264.</a></li><li><a class="nounderline abstract_t">Silverstein J, Maclaren N, Riley W, et al. Immunosuppression with azathioprine and prednisone in recent-onset insulin-dependent diabetes mellitus. N Engl J Med 1988; 319:599.</a></li><li><a class="nounderline abstract_t">Cook JJ, Hudson I, Harrison LC, et al. Double-blind controlled trial of azathioprine in children with newly diagnosed type I diabetes. Diabetes 1989; 38:779.</a></li><li><a class="nounderline abstract_t">Harrison LC, Colman PG, Dean B, et al. Increase in remission rate in newly diagnosed type I diabetic subjects treated with azathioprine. Diabetes 1985; 34:1306.</a></li><li><a class="nounderline abstract_t">Gottlieb PA, Quinlan S, Krause-Steinrauf H, et al. Failure to preserve beta-cell function with mycophenolate mofetil and daclizumab combined therapy in patients with new- onset type 1 diabetes. Diabetes Care 2010; 33:826.</a></li><li><a class="nounderline abstract_t">Moran A, Bundy B, Becker DJ, et al. Interleukin-1 antagonism in type 1 diabetes of recent onset: two multicentre, randomised, double-blind, placebo-controlled trials. Lancet 2013; 381:1905.</a></li><li><a class="nounderline abstract_t">Greenbaum CJ, Serti E, Lambert K, et al. IL-6 receptor blockade does not slow β cell loss in new-onset type 1 diabetes. JCI Insight 2021; 6.</a></li><li><a class="nounderline abstract_t">Piemonti L, Keymeulen B, Gillard P, et al. Ladarixin, an inhibitor of the interleukin-8 receptors CXCR1 and CXCR2, in new-onset type 1 diabetes: A multicentre, randomized, double-blind, placebo-controlled trial. Diabetes Obes Metab 2022; 24:1840.</a></li><li><a class="nounderline abstract_t">von Herrath M, Bain SC, Bode B, et al. Anti-interleukin-21 antibody and liraglutide for the preservation of β-cell function in adults with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Diabetes Endocrinol 2021; 9:212.</a></li><li><a class="nounderline abstract_t">Buckingham B, Beck RW, Ruedy KJ, et al. Effectiveness of early intensive therapy on β-cell preservation in type 1 diabetes. Diabetes Care 2013; 36:4030.</a></li><li><a class="nounderline abstract_t">Kordonouri O, Pankowska E, Rami B, et al. Sensor-augmented pump therapy from the diagnosis of childhood type 1 diabetes: results of the Paediatric Onset Study (ONSET) after 12 months of treatment. Diabetologia 2010; 53:2487.</a></li><li><a class="nounderline abstract_t">Boughton CK, Allen JM, Ware J, et al. Closed-Loop Therapy and Preservation of C-Peptide Secretion in Type 1 Diabetes. N Engl J Med 2022; 387:882.</a></li><li><a class="nounderline abstract_t">Ludvigsson J, Faresjö M, Hjorth M, et al. GAD treatment and insulin secretion in recent-onset type 1 diabetes. N Engl J Med 2008; 359:1909.</a></li><li><a class="nounderline abstract_t">Wherrett DK, Bundy B, Becker DJ, et al. Antigen-based therapy with glutamic acid decarboxylase (GAD) vaccine in patients with recent-onset type 1 diabetes: a randomised double-blind trial. Lancet 2011; 378:319.</a></li><li><a class="nounderline abstract_t">Ludvigsson J, Sumnik Z, Pelikanova T, et al. Intralymphatic Glutamic Acid Decarboxylase With Vitamin D Supplementation in Recent-Onset Type 1 Diabetes: A Double-Blind, Randomized, Placebo-Controlled Phase IIb Trial. Diabetes Care 2021; 44:1604.</a></li><li><a class="nounderline abstract_t">Madani S, Amanzadi M, Aghayan HR, et al. Investigating the safety and efficacy of hematopoietic and mesenchymal stem cell transplantation for treatment of T1DM: a systematic review and meta-analysis. Syst Rev 2022; 11:82.</a></li><li><a class="nounderline abstract_t">Yu J, Sharma P, Girgis CM, Gunton JE. Vitamin D and Beta Cells in Type 1 Diabetes: A Systematic Review. Int J Mol Sci 2022; 23.</a></li><li><a class="nounderline abstract_t">Passali M, Josefsen K, Frederiksen JL, Antvorskov JC. Current Evidence on the Efficacy of Gluten-Free Diets in Multiple Sclerosis, Psoriasis, Type 1 Diabetes and Autoimmune Thyroid Diseases. Nutrients 2020; 12.</a></li><li><a class="nounderline abstract_t">Khorshidi M, Sayyari A, Aryaeian N, et al. Effects of omega-3 supplementation on endothelial function, vascular structure, and metabolic parameters in adolescents with type 1 diabetes mellitus: A randomized clinical trial. Front Nutr 2022; 9:962773.</a></li><li><a class="nounderline abstract_t">O'Mahoney LL, Dunseath G, Churm R, et al. Omega-3 polyunsaturated fatty acid supplementation versus placebo on vascular health, glycaemic control, and metabolic parameters in people with type 1 diabetes: a randomised controlled preliminary trial. Cardiovasc Diabetol 2020; 19:127.</a></li></ol></div><div id="topicVersionRevision">Topic 1811 Version 39.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25998289" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Current state of type 1 diabetes treatment in the U.S.: updated data from the T1D Exchange clinic registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30657336" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : State of Type 1 Diabetes Management and Outcomes from the T1D Exchange in 2016-2018.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32478819" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Out-of-Pocket Spending for Insulin, Diabetes-Related Supplies, and Other Health Care Services Among Privately Insured US Patients With Type 1 Diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31886730" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Estimated Lifetime Economic Burden of Type 1 Diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28427059" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : The Burden of Diabetes: Emerging Data.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27118163" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Diabetes distress in adults with type 1 diabetes: Prevalence, incidence and change over time.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30089716" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : βCell dysfunction exists more than 5 years before type 1 diabetes diagnosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23863814" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Acceleration of the loss of the first-phase insulin response during the progression to type 1 diabetes in diabetes prevention trial-type 1 participants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32457058" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : C-Peptide Levels in Subjects Followed Longitudinally Before and After Type 1 Diabetes Diagnosis in TrialNet.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22688329" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Fall in C-peptide during first 2 years from diagnosis: evidence of at least two distinct phases from composite Type 1 Diabetes TrialNet data.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31180194" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33658358" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Teplizumab improves and stabilizes beta cell function in antibody-positive high-risk individuals.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33658358" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Teplizumab improves and stabilizes beta cell function in antibody-positive high-risk individuals.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36920087" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Abatacept for Delay of Type 1 Diabetes Progression in Stage 1 Relatives at Risk: A Randomized, Double-Masked, Controlled Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36920087" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Abatacept for Delay of Type 1 Diabetes Progression in Stage 1 Relatives at Risk: A Randomized, Double-Masked, Controlled Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37708415" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Hydroxychloroquine in Stage 1 Type 1 Diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15855569" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Effects of oral insulin in relatives of patients with type 1 diabetes: The Diabetes Prevention Trial--Type 1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19120293" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Update on worldwide efforts to prevent type 1 diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21610124" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Long-term outcome of individuals treated with oral insulin: diabetes prevention trial-type 1 (DPT-1) oral insulin trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29164254" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Effect of Oral Insulin on Prevention of Diabetes in Relatives of Patients With Type 1 Diabetes: A Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25898052" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Effects of high-dose oral insulin on immune responses in children at high risk for type 1 diabetes: the Pre-POINT randomized clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31256036" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Oral insulin therapy for primary prevention of type 1 diabetes in infants with high genetic risk: the GPPAD-POInT (global platform for the prevention of autoimmune diabetes primary oral insulin trial) study protocol.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20522167" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Parenteral insulin suppresses T cell proliferation to islet antigens.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18814906" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Nasal insulin to prevent type 1 diabetes in children with HLA genotypes and autoantibodies conferring increased risk of disease: a double-blind, randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18814906" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Nasal insulin to prevent type 1 diabetes in children with HLA genotypes and autoantibodies conferring increased risk of disease: a double-blind, randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15043959" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : European Nicotinamide Diabetes Intervention Trial (ENDIT): a randomised controlled trial of intervention before the onset of type 1 diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25519448" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Prevalence of detectable C-Peptide according to age at diagnosis and duration of type 1 diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25519449" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Most people with long-duration type 1 diabetes in a large population-based study are insulin microsecretors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20699420" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Residual insulin production and pancreaticß-cell turnover after 50 years of diabetes: Joslin Medalist Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31264968" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Residualβcell function and monogenic variants in long-duration type 1 diabetes patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9518395" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Effect of intensive therapy on residual beta-cell function in patients with type 1 diabetes in the diabetes control and complications trial. A randomized, controlled trial. The Diabetes Control and Complications Trial Research Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14510860" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Characteristics of Type 1 diabetes of over 50 years duration (the Golden Years Cohort).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21447665" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Protection from retinopathy and other complications in patients with type 1 diabetes of extreme duration: the joslin 50-year medalist study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8366922" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27209482" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Correlation Among Hypoglycemia, Glycemic Variability, and C-Peptide Preservation After Alefacept Therapy in Patients with Type 1 Diabetes Mellitus: Analysis of Data from the Immune Tolerance Network T1DAL Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25422169" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Demonstration of an intrinsic relationship between endogenous C-peptide concentration and determinants of glycemic control in type 1 diabetes following islet transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12610045" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Beta-cell function and the development of diabetes-related complications in the diabetes control and complications trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36657975" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Predictive Value of C-Peptide Measures for Clinical Outcomes ofβ-Cell Replacement Therapy in Type 1 Diabetes: Report From the Collaborative Islet Transplant Registry (CITR).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24089509" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Impact of C-peptide preservation on metabolic and clinical outcomes in the Diabetes Control and Complications Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33303639" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Clinical Impact of Residual C-Peptide Secretion in Type 1 Diabetes on Glycemia and Microvascular Complications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22996144" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Continuous glucose monitoring after islet transplantation in type 1 diabetes: an excellent graft function (β-score greater than 7) Is required to abrogate hyperglycemia, whereas a minimal function is necessary to suppress severe hypoglycemia (β-score greater than 3).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30012675" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Low-Dose Anti-Thymocyte Globulin (ATG) Preservesβ-Cell Function and Improves HbA1c in New-Onset Type 1 Diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19366957" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Etanercept treatment in children with new-onset type 1 diabetes: pilot randomized, placebo-controlled, double-blind study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33207093" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Golimumab and Beta-Cell Function in Youth with New-Onset Type 1 Diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36576974" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Two-Year Follow-up From the T1GER Study: Continued Off-Therapy Metabolic Improvements in Children and Young Adults With New-Onset T1D Treated With Golimumab and Characterization of Responders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19875613" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Defects in IL-2R signaling contribute to diminished maintenance of FOXP3 expression in CD4(+)CD25(+) regulatory T-cells of type 1 diabetic subjects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18468463" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Central role of defective interleukin-2 production in the triggering of islet autoimmune destruction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22721971" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Rapamycin/IL-2 combination therapy in patients with type 1 diabetes augments Tregs yet transiently impairsβ-cell function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28292965" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Repurposed JAK1/JAK2 Inhibitor Reverses Established Autoimmune Insulitis in NOD Mice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/38055252" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Baricitinib andβ-Cell Function in Patients with New-Onset Type 1 Diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37607392" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Teplizumab: A Disease-Modifying Therapy for Type 1 Diabetes That Preservesβ-Cell Function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12037148" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15919798" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : A single course of anti-CD3 monoclonal antibody hOKT3gamma1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23835333" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Teplizumab (anti-CD3 mAb) treatment preserves C-peptide responses in patients with new-onset type 1 diabetes in a randomized controlled trial: metabolic and immunologic features at baseline identify a subgroup of responders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30569273" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Treatment of type 1 diabetes with teplizumab: clinical and immunological follow-up after 7 years from diagnosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21719095" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Teplizumab for treatment of type 1 diabetes (Protégéstudy): 1-year results from a randomised, placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14693724" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : C-peptide is the appropriate outcome measure for type 1 diabetes clinical trials to preserve beta-cell function: report of an ADA workshop, 21-22 October 2001.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23801579" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Teplizumab preserves C-peptide in recent-onset type 1 diabetes: two-year results from the randomized, placebo-controlled Protégétrial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37861217" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Teplizumab andβ-Cell Function in Newly Diagnosed Type 1 Diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19940299" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Rituximab, B-lymphocyte depletion, and preservation of beta-cell function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24026563" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : B-lymphocyte depletion with rituximab andβ-cell function: two-year results.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21719096" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24296850" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Costimulation modulation with abatacept in patients with recent-onset type 1 diabetes: follow-up 1 year after cessation of treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30830871" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : B lymphocyte alterations accompany abatacept resistance in new-onset type 1 diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29925930" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Elevated T cell levels in peripheral blood predict poor clinical response following rituximab treatment in new-onset type 1 diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29925930" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Elevated T cell levels in peripheral blood predict poor clinical response following rituximab treatment in new-onset type 1 diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24622414" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Targeting of memory T cells with alefacept in new-onset type 1 diabetes (T1DAL study): 12 month results of a randomised, double-blind, placebo-controlled phase 2 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26193635" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Alefacept provides sustained clinical and immunological effects in new-onset type 1 diabetes patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30967424" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Low-Dose Anti-Thymocyte Globulin Preserves C-Peptide, Reduces HbA1c, and Increases Regulatory to Conventional T-Cell Ratios in New-Onset Type 1 Diabetes: Two-Year Clinical Trial Data.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26606968" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Type 1 diabetes immunotherapy using polyclonal regulatory T cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24704576" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Therapy of type 1 diabetes with CD4(+)CD25(high)CD127-regulatory T cells prolongs survival of pancreatic islets - results of one year follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22723342" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Administration of CD4+CD25highCD127- regulatory T cells preservesβ-cell function in type 1 diabetes in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34324441" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : The effect of low-dose IL-2 and Treg adoptive cell therapy in patients with type 1 diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35563276" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Dendritic Cells and Their Immunotherapeutic Potential for Treating Type 1 Diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21680720" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Phase I (safety) study of autologous tolerogenic dendritic cells in type 1 diabetic patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28739632" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Therapeutic potential of mesenchymal stem cells for diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23154532" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Long term effects of the implantation of Wharton's jelly-derived mesenchymal stem cells from the umbilical cord for newly-onset type 1 diabetes mellitus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25204974" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Preservedβ-cell function in type 1 diabetes by mesenchymal stromal cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35725652" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Mesenchymal stem cell transplantation in newly diagnosed type-1 diabetes patients: a phase I/II randomized placebo-controlled clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27258578" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Current outcomes in islet versus solid organ pancreas transplant forβ-cell replacement in type 1 diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29288549" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Transplantation of macroencapsulated human islets within the bioartificial pancreasβAir to patients with type 1 diabetes mellitus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26156291" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Development of an encapsulated stem cell-based therapy for diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35370989" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Stem Cell Transplantation in the Treatment of Type 1 Diabetes Mellitus: From Insulin Replacement to Beta-Cell Replacement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32618633" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : The role of beta-cell dysfunction in early type 1 diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29988125" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Verapamil and beta cell function in adults with recent-onset type 1 diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36826844" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Effect of Verapamil on Pancreatic Beta Cell Function in Newly Diagnosed Pediatric Type 1 Diabetes: A Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36826834" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Effect of Tight Glycemic Control on Pancreatic Beta Cell Function in Newly Diagnosed Pediatric Type 1 Diabetes: A Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34214479" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Imatinib therapy for patients with recent-onset type 1 diabetes: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25660258" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : The 6 year incidence of diabetes-associated autoantibodies in genetically at-risk children: the TEDDY study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23835325" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Patterns ofβ-cell autoantibody appearance and genetic associations during the first years of life.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10990077" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : No effect of oral insulin on residual beta-cell function in recent-onset type I diabetes (the IMDIAB VII). IMDIAB Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19690081" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : No effect of the altered peptide ligand NBI-6024 on beta-cell residual function and insulin needs in new-onset type 1 diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19040615" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Proinsulin peptide immunotherapy in type 1 diabetes: report of a first-in-man Phase I safety study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19931408" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Autoantigen-specific regulatory T cells induced in patients with type 1 diabetes mellitus by insulin B-chain immunotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23274889" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Fecal microbiota composition differs between children withβ-cell autoimmunity and those without.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33106354" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Faecal microbiota transplantation halts progression of human new-onset type 1 diabetes in a randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35299968" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Adjuvant Probiotics of Lactobacillus salivarius subsp. salicinius AP-32, L. johnsonii MH-68, and Bifidobacterium animalis subsp. lactis CP-9 Attenuate Glycemic Levels and Inflammatory Cytokines in Patients With Type 1 Diabetes Mellitus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34174128" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : A high potency multi-strain probiotic improves glycemic control in children with new-onset type 1 diabetes mellitus: A randomized, double-blind, and placebo-controlled pilot study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33771763" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Lack of effect of Lactobacillus rhamnosus GG and Bifidobacterium lactis Bb12 on beta-cell function in children with newly diagnosed type 1 diabetes: a randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30238182" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Probiotic intervention in infancy is not associated with development of beta cell autoimmunity and type 1 diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31188437" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Effect of Prebiotic on Microbiota, Intestinal Permeability, and Glycemic Control in Children With Type 1 Diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3125434" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Factors associated with early remission of type I diabetes in children treated with cyclosporine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2903105" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Cyclosporin-induced remission of IDDM after early intervention. Association of 1 yr of cyclosporin treatment with enhanced insulin secretion. The Canadian-European Randomized Control Trial Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2210078" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Limited duration of remission of insulin dependency in children with recent overt type I diabetes treated with low-dose cyclosporin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3045545" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Immunosuppression with azathioprine and prednisone in recent-onset insulin-dependent diabetes mellitus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2656346" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Double-blind controlled trial of azathioprine in children with newly diagnosed type I diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3905463" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Increase in remission rate in newly diagnosed type I diabetic subjects treated with azathioprine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20067954" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Failure to preserve beta-cell function with mycophenolate mofetil and daclizumab combined therapy in patients with new- onset type 1 diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23562090" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Interleukin-1 antagonism in type 1 diabetes of recent onset: two multicentre, randomised, double-blind, placebo-controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34747368" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : IL-6 receptor blockade does not slowβcell loss in new-onset type 1 diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35589610" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Ladarixin, an inhibitor of the interleukin-8 receptors CXCR1 and CXCR2, in new-onset type 1 diabetes: A multicentre, randomized, double-blind, placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33662334" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Anti-interleukin-21 antibody and liraglutide for the preservation ofβ-cell function in adults with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled, phase 2 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24130350" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Effectiveness of early intensive therapy onβ-cell preservation in type 1 diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20711715" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Sensor-augmented pump therapy from the diagnosis of childhood type 1 diabetes: results of the Paediatric Onset Study (ONSET) after 12 months of treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36069870" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Closed-Loop Therapy and Preservation of C-Peptide Secretion in Type 1 Diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18843118" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : GAD treatment and insulin secretion in recent-onset type 1 diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21714999" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : Antigen-based therapy with glutamic acid decarboxylase (GAD) vaccine in patients with recent-onset type 1 diabetes: a randomised double-blind trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34021020" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : Intralymphatic Glutamic Acid Decarboxylase With Vitamin D Supplementation in Recent-Onset Type 1 Diabetes: A Double-Blind, Randomized, Placebo-Controlled Phase IIb Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35501872" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : Investigating the safety and efficacy of hematopoietic and mesenchymal stem cell transplantation for treatment of T1DM: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36430915" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : Vitamin D and Beta Cells in Type 1 Diabetes: A Systematic Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32752175" id="rid120" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>121 : Current Evidence on the Efficacy of Gluten-Free Diets in Multiple Sclerosis, Psoriasis, Type 1 Diabetes and Autoimmune Thyroid Diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35938123" id="rid121" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>122 : Effects of omega-3 supplementation on endothelial function, vascular structure, and metabolic parameters in adolescents with type 1 diabetes mellitus: A randomized clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32787879" id="rid122" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>123 : Omega-3 polyunsaturated fatty acid supplementation versus placebo on vascular health, glycaemic control, and metabolic parameters in people with type 1 diabetes: a randomised controlled preliminary trial.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
